BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

436 related articles for article (PubMed ID: 27636236)

  • 21. Hedgehog inhibitors in the treatment of advanced basal cell carcinoma: risks and benefits.
    Villani A; Cinelli E; Fabbrocini G; Lallas A; Scalvenzi M
    Expert Opin Drug Saf; 2020 Dec; 19(12):1585-1594. PubMed ID: 33054455
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sonidegib: A Review in Locally Advanced Basal Cell Carcinoma.
    Burness CB; Scott LJ
    Target Oncol; 2016 Apr; 11(2):239-46. PubMed ID: 26867946
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Long-term efficacy and safety of sonidegib in patients with advanced basal cell carcinoma: 42-month analysis of the phase II randomized, double-blind BOLT study.
    Dummer R; Guminksi A; Gutzmer R; Lear JT; Lewis KD; Chang ALS; Combemale P; Dirix L; Kaatz M; Kudchadkar R; Loquai C; Plummer R; Schulze HJ; Stratigos AJ; Trefzer U; Squittieri N; Migden MR
    Br J Dermatol; 2020 Jun; 182(6):1369-1378. PubMed ID: 31545507
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Sonidegib (Odomzo°) and extensive basal cell carcinoma.
    Prescrire Int; 2017 Jan; 26(178):14-15. PubMed ID: 30730637
    [No Abstract]   [Full Text] [Related]  

  • 25. A Review of Hedgehog Inhibitors Sonidegib and Vismodegib for Treatment of Advanced Basal Cell Carcinoma.
    Migden M; Farberg AS; Dummer R; Squittieri N; Hanke CW
    J Drugs Dermatol; 2021 Feb; 20(2):156-165. PubMed ID: 33538567
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Emerging drugs and combination strategies for basal cell carcinoma.
    Dreier J; Dummer R; Felderer L; Nägeli M; Gobbi S; Kunstfeld R
    Expert Opin Emerg Drugs; 2014 Sep; 19(3):353-65. PubMed ID: 24773312
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Assessment of various efficacy outcomes using ERIVANCE-like criteria in patients with locally advanced basal cell carcinoma receiving sonidegib: results from a preplanned sensitivity analysis.
    Gutzmer R; Robert C; Loquai C; Schadendorf D; Squittieri N; Arntz R; Martelli S; Dummer R
    BMC Cancer; 2021 Nov; 21(1):1244. PubMed ID: 34798846
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Phase I and phase II sonidegib and vismodegib clinical trials for the treatment of paediatric and adult MB patients: a systemic review and meta-analysis.
    Li Y; Song Q; Day BW
    Acta Neuropathol Commun; 2019 Jul; 7(1):123. PubMed ID: 31362788
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Recovery of taste organs and sensory function after severe loss from Hedgehog/Smoothened inhibition with cancer drug sonidegib.
    Kumari A; Ermilov AN; Grachtchouk M; Dlugosz AA; Allen BL; Bradley RM; Mistretta CM
    Proc Natl Acad Sci U S A; 2017 Nov; 114(48):E10369-E10378. PubMed ID: 29133390
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Vismodegib and the hedgehog pathway: a new treatment for basal cell carcinoma.
    Cirrone F; Harris CS
    Clin Ther; 2012 Oct; 34(10):2039-50. PubMed ID: 23036338
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Vismodegib and Sonidegib in Locally Advanced and Metastatic Basal Cell Carcinoma: Update on Hedgehog Pathway Inhibitors.
    Kurnia Wijaya J; Djawad K; Wahab S; Nurdin A; Irawan Anwar A
    Actas Dermosifiliogr; 2022 May; 113(5):443-450. PubMed ID: 35697404
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Vismodegib: an inhibitor of the Hedgehog signaling pathway in the treatment of basal cell carcinoma.
    Proctor AE; Thompson LA; O'Bryant CL
    Ann Pharmacother; 2014 Jan; 48(1):99-106. PubMed ID: 24259609
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Expanded access study of patients with advanced basal cell carcinoma treated with the Hedgehog pathway inhibitor, vismodegib.
    Chang AL; Solomon JA; Hainsworth JD; Goldberg L; McKenna E; Day BM; Chen DM; Weiss GJ
    J Am Acad Dermatol; 2014 Jan; 70(1):60-9. PubMed ID: 24189279
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Vismodegib, itraconazole and sonidegib as hedgehog pathway inhibitors and their relative competencies in the treatment of basal cell carcinomas.
    Wahid M; Jawed A; Mandal RK; Dar SA; Khan S; Akhter N; Haque S
    Crit Rev Oncol Hematol; 2016 Feb; 98():235-41. PubMed ID: 26614022
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Efficacy and safety of sonidegib for the management of basal cell carcinoma: a drug safety evaluation.
    Villani A; Scalvenzi M; Micali G; Lacarrubba F; Genco L; Ruggiero A; Fornaro L; Guerrasio G; Potestio L
    Expert Opin Drug Saf; 2023; 22(7):525-531. PubMed ID: 37326221
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Dynamic optical coherence tomography evaluation in locally advanced basal cell carcinoma during sonidegib treatment.
    Cantisani C; Musolff N; Longo C; Di Guardo A; Rovaldi E; Rossi G; Sasso F; Farnetani F; Rega F; Bánvölgyiv A; Azzella G; Paolino G; Pellacani G
    J Eur Acad Dermatol Venereol; 2024 May; 38(5):967-973. PubMed ID: 38270330
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Sonidegib with and Without Adjunctive Treatment for Locally Advanced Basal Cell Carcinomas.
    Villani A; Fabbrocini G; Costa C; Potestio L; Scalvenzi M
    Oncologist; 2022 Jun; 27(6):e533. PubMed ID: 35436344
    [No Abstract]   [Full Text] [Related]  

  • 38. Locally advanced basal cell carcinoma: Real-life data with sonidegib.
    Toffoli L; Conforti C; Zelin E; Vezzoni R; Agozzino M; di Meo N; Zalaudek I
    Dermatol Ther; 2022 Jun; 35(6):e15441. PubMed ID: 35279921
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Sonidegib and vismodegib in the treatment of patients with locally advanced basal cell carcinoma: a joint expert opinion.
    Dummer R; Ascierto PA; Basset-Seguin N; Dréno B; Garbe C; Gutzmer R; Hauschild A; Krattinger R; Lear JT; Malvehy J; Schadendorf D; Grob JJ
    J Eur Acad Dermatol Venereol; 2020 Sep; 34(9):1944-1956. PubMed ID: 31990414
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Smoothened receptor inhibitor vismodegib for the treatment of basal cell carcinoma: a retrospective analysis of efficacy and side effects.
    Bánvölgyi A; Anker P; Lőrincz K; Kiss N; Márton D; Fésűs L; Gyöngyösi N; Wikonkál N
    J Dermatolog Treat; 2020 Jun; 31(4):387-398. PubMed ID: 31039644
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 22.